Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
Publication in refereed journal


Times Cited
Web of Science430WOS source URL (as at 05/08/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractBACKGROUND Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.
All Author(s) ListWedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers T, Thach C, Fogel R, Patalano F, Vogelmeier CF
Journal nameNew England Journal of Medicine,New England Journal of Medicine
Detailed descriptionDOI: 10.1056/NEJMoa1516385.
Year2016
Month6
Day9
Volume Number374
Issue Number23
PublisherMASSACHUSETTS MEDICAL SOC
Pages2222 - 2234
ISSN0028-4793
eISSN1533-4406
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesGeneral & Internal Medicine; Medicine, General & Internal

Last updated on 2020-06-08 at 02:44